<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654482</url>
  </required_header>
  <id_info>
    <org_study_id>2016_018</org_study_id>
    <nct_id>NCT03654482</nct_id>
  </id_info>
  <brief_title>SuperSeton Pilot Studie</brief_title>
  <official_title>Pilot Study of SuperSeton Placement in Patients With Perianal Fistulas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Proctos Kliniek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MediShield B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Delft University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Perianal fistulas are a common incapacitating problem. Many patients are treated&#xD;
      by seton drainage to prevent recurrent abscess formation. Nowadays, vessel loops or sutures&#xD;
      are used for drainage. The knot of these seton drains can cause complaints of pain or&#xD;
      tenderness if it presses against the external opening of the fistula or even slides in to the&#xD;
      fistula tract. Medishield B.V. designed a knotless seton drain, the SuperSeton. This could&#xD;
      decrease the pain complaints caused by the knot.&#xD;
&#xD;
      Objective: The aim of this study is to determine the feasibility of SuperSeton placement in&#xD;
      patients with perianal fistulas.&#xD;
&#xD;
      Study design: The design of the study is a feasibility study.&#xD;
&#xD;
      Study population: Patients (≥ 18 years) with perianal fistulas (ever) treated with a knotted&#xD;
      seton are eligible.&#xD;
&#xD;
      Intervention: The SuperSeton will be placed at the outpatient clinic in patients that already&#xD;
      have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients&#xD;
      do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day&#xD;
      care setting instead of a regular seton.&#xD;
&#xD;
      Main study parameters/endpoints: The primary outcome is seton failure (loosening of the&#xD;
      seton). Secondary outcomes are time of procedure, complications and quality of life measured&#xD;
      by the PDAI ('Perianal Disease Activity Index').&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation: The SuperSeton will&#xD;
      be placed in patients with perianal fistulas (ever) treated with a conventional knotted&#xD;
      seton. There are no additional risks involved. The seton will be placed at the outpatient&#xD;
      clinic in patients with a seton in situ, or at the operating theatre in day care setting in&#xD;
      patients with a perianal abscess without a seton. The material that is used for the Setons is&#xD;
      of medical grade polyurethane, this is the same material of catheters that are already used&#xD;
      in clinical practice (instech BTPU 027). The Setons including the insert (BTPU) are supplied&#xD;
      sterile (Synergy Health). Sample size calculation: A group of 60 patients will be included to&#xD;
      determine feasibility of the SuperSeton. The proposed treatment protocol is considered&#xD;
      feasible if at least 70% of the SuperSetons stay in place.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2016</start_date>
  <completion_date type="Actual">July 4, 2018</completion_date>
  <primary_completion_date type="Actual">July 4, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seton failure</measure>
    <time_frame>3 months</time_frame>
    <description>Loosening of the seton</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perianal Disease Activity Index score</measure>
    <time_frame>3 months</time_frame>
    <description>The PDAI is the gold standard for evaluating the severity of perianal disease. It includes five items: discharge, pain, restriction of sexual activity, type of perianal disease, and degree of induration. Each category is graded on a five-point Likert scale ranging from no symptoms to severe symptoms. The sum of the five subscores represents the total PDAI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing complications</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants experiencing peri-operative complications, an increase in perianal pain complains, and perianal abscesses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring surgical re-interventions</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Perianal Fistula</condition>
  <condition>Perianal Crohn Disease</condition>
  <arm_group>
    <arm_group_label>SuperSeton arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SuperSeton</intervention_name>
    <description>The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.</description>
    <arm_group_label>SuperSeton arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Perianal fistula with a seton in situ or a recurrent perianal fistula for which a new&#xD;
             seton will be placed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a pacemaker or an ICD in situ&#xD;
&#xD;
          -  Rectovaginal fistula&#xD;
&#xD;
          -  Patients with a stoma&#xD;
&#xD;
          -  Life expectancy &lt; 2 years&#xD;
&#xD;
          -  The inability of reading/understanding and filling in the questionnaires&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit the understanding and giving of&#xD;
             informed consent&#xD;
&#xD;
          -  Participation in another trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. dr. W.A. Bemelman</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Knotless seton</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Perianal Disease Activity Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03654482/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

